Consumers' views on generic medicines: A reiew of the literature

International Journal of Pharmacy Practice

Volumn 17, Issue 2, 2009, Pages 79-88

  Hassali, Mohamed Aami Ahmad ^a   Shafie, Asrul A ^a   Jamshed, Shazia ^a   Ibrahim, Mohamed I M ^a   Awaisu, Ahmed ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Consumer; Generic medicines; Knowledge; Perceptions; Policy

Indexed keywords

GENERIC DRUG; WARFARIN;

BIOEQUIVALENCE; CONSUMER ADVOCACY; CONSUMER ATTITUDE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEVELOPED COUNTRY; DRUG COST; DRUG FORMULATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG QUALITY; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; GEOGRAPHIC DISTRIBUTION; HEALTH BELIEF; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; HUMAN RELATION; MEDLINE; PATIENT EDUCATION; POPULATION EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REIMBURSEMENT; REVIEW; TREND STUDY;

DRUGS, GENERIC; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PATIENT EDUCATION AS TOPIC; PROFESSIONAL-PATIENT RELATIONS; REIMBURSEMENT MECHANISMS; SOCIOECONOMIC FACTORS;

EID: 63049134441     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/ijpp/17.02.0002     Document Type: Review

References (32)

1. Carroll NV. Impact of generic and therapeutic interchange incentives on community pharmacy. Am Pharm 1995; NS35(7): 27-34.
2. Karim SS et al. Potential savings from generic prescribing and generic substitution in South Africa. Health Policy Plan 1996; 11(2): 198-205.
3. Kirking DM et al. Economics and structure of the generic pharmaceutical industry. J Am Pharm Assoc (Wash) 2001; 41(4): 578-584.
4. Pearce GA et al. Bioequivalence: how, why, and what does it really mean? J Pharm Pract Res 2004; 34: 195-200.
5. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J 2002; 43(4): 462-469.
6. Lofgren H. Generic drugs: international trends and policy developments in Australia. Aust Health Rev 2004; 27(1): 39-48.
7. Haas JS et al. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med 2005; 142(11): 891-897.
8. McGavock H. Strategies to improve the cost effectiveness of general practitioner prescribing. An international perspective. PharmacoEconomics 1997; 12(3): 307-311.
9. McGavock H. Generic substitution-issues relating to the Australian experience. Pharmacoepidemiol Drug Saf 2001; 10(6): 555-556.
10. Bearden WO, Mason JB. Consumer-perceived risk and attitudes toward generically prescribed drugs. J Appl Psychol 1978; 63(6): 741-746.
11. Lambert ZV et al. Predispositions toward generic drug acceptance. J Consum Res 1980; 7(1): 14-23.
12. Mason JB, Bearden WO. Generic drugs: consumer, pharmacist and physician perceptions of the issues. J Consum Aff 1980; 14(1): 193-206.
13. Shepherd MD. Consumer drug purchases are based on perceptions of quality, survey on generics finds. Am J Hosp Pharm 1988; 45: 1245.
14. Tootelian DH et al. Branded versus generic prescription drugs: perceptions of risk, efficacy, safety, and value. J Health Care Mark 1988; 8(3): 26-29.
15. Podulka M et al. Consumers' attitudes toward generic drugs. J Pharm Mark Manag 1989; 4(1): 93-104.
16. Kendall KW et al. Consumer response to generic/chemically equivalent drugs. J Public Policy Mark 1991; 10(2): 182-201.
17. Rosendahl I. Consumers on generics: some clues on their views from AARP. Drug Topics 1994: May (suppl): 54s-56s.
18. Muirhead G. How consumers see managed care. Drug Topics 1994; May: 40-54.
19. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash) 2000; 40(3): 378-383.
20. Momani A et al. Drug-management strategies: consumers' perspectives. J Manage Care Pharm 2000; 6(2): 122-128.
21. Valles JA et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy 2003; 65(3): 269-275.
22. Bertoldi AD et al. Generic drugs in Brazil: known by many, used by few. Cadernos de saude publica/Ministerio da Saude, Fundacao Oswaldo Cruz, Escola Nacional de Saude Publica 2005; 21(6): 1808-1815.
23. Hassali MA et al. Generic medicines: perceptions of consumers in Melbourne Australia. Int J Pharm Pract 2005; 13(4): 257-264.
24. Pereira JA et al. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Pharmacol 2005; 12(3): e229-e239.
25. Kjoenniksen I et al. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006; 28(5): 284-289.
26. Heikkila R et al. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Policy 2007; 82(3): 366-374.
27. Figueiras JM et al. People's views on the level of agreement of generic medicines for different illnesses. Pharm World Sci 2008; 30: 590-594.
28. Iosifescu A et al. Beliefs about generic drugs among elderly adults in hospital-based primary care practices. Patient Educ Counsel 2008; 73: 377-383.
29. Al-Gedadi NA et al. A pilot survey on perceptions and knowledge of generic medicines among consumers in Penang, Malaysia. Pharm Pract 2008; 6(2): 93-97.
30. World Health Organization. The World Medicines Situation (2004). WHO/EDM/PAR/2004.5. Geneva: World Health Organization, 2004.
31. Boxtel CJv. Some safety aspects of generic prescribing. Int J Risk Saf Med 2004; 16(3): 191.
32. Gaither CA et al. Consumers' views on generic medications. J Am Pharm Assoc 2001; 41(5): 729-736.